Trial NCT04444674
Publication Madhi S, N Engl J Med, 2021
Primary outcome on the report: The primary end point was efficacy against nucleic acid amplification test–confirmed symptomatic Covid-19 with onset more than 14 days after the second injection in participants who were seronegative at randomization.
The safety analysis evaluated the occurrence of solicited local and systemic reactogenicity within the first 7 days after an injection, unsolicited adverse events within 28 days after an injection, changes from baseline in safety laboratory measures, and serious adverse events.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.